Abpro Holdings, Inc. ABP 深 滬
已收盤 02-06 16:00:00 美东时间
1.50
0.000
0.00%
華盛通- 最 高1.55
- 今 開1.49
- 成交量 2.38万股
- 最 低 1.46
- 昨 收 1.50
- 總市值 407.44万
- 52周最高 34.65
- 市盈率 靜 --
- 換手率 0.87%
- 52周最低 1.44
- 委 比 1.77%
- 總股本 271.63万
- 歷史最高 264.00
- 量 比 0.74
- 振 幅 6.00%
- 歷史最低 1.44
- 每 手 1
- 風險率 5.82%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Abpro and Celltrion to Start Global Trial of Targeted HER2+ Cancer Antibody in Early 2026
Abpro Holdings, Inc. (NASDAQ:ABP), a biotechnology company developing next-generation antibody therapeutics for solid tumors, today announced, together with its co-development partner Celltrion, Inc., that the U.S. Food
01-06 20:09
Abpro and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72
Abpro Holdings, Inc. and Celltrion, Inc. announced the FDA clearance of the IND application for ABP-102 / CT-P72, a multispecific HER2 × CD3 T-cell engager targeting HER2-positive solid tumors. This clearance enables the initiation of a Phase 1 clinical trial in the first half of 2026 to evaluate safety, tolerability, pharmacokinetics, and efficacy. ABP-102 / CT-P72 is designed to selectively target HER2-overexpressing tumor cells while engaging ...
01-06 12:00
Abpro Holdings Submits IND Application for Cancer Drug
An announcement from Abpro Holdings ( ($ABP) ) is now available. On December 15...
2025-12-15 20:50
Abpro Granted Nasdaq Listing Extension to Pursue Compliance and Strategic Objectives
Abpro Holdings, a biotechnology company, received a Nasdaq extension to regain compliance with listing requirements. The company has reduced operating expenses by ~60% and completed a reverse stock split. It plans to increase shareholders’ equity via flexible financing and achieve long-term milestones. Lead candidate ABP-102 is on track for first-in-human trials in 2026. Abpro remains focused on executing its compliance plan while advancing its p...
2025-12-09 12:00
Abpro To Present Data For CT-P72/ABP-102 Tetravalent Bispecific Antibody At Society For Immunotherapy Of Cancer
Abpro Corporation (Nasdaq: ABP) ("Abpro") and Celltrion, Inc. ("Celltrion") today announced that they will present new preclinical data for CT-P72/ABP-102, a tetravalent bispecific antibody targeting HER2 and CD3, at the
2025-11-04 22:17
Abpro Announces 1-for-30 Reverse Stock Split Effective November 3, 2025
Abpro Holdings, Inc. implemented a 1-for-30 reverse stock split to comply with Nasdaq listing standards and support future growth. The company reduced its operating costs by ~60% and is leveraging its DiversImmune® platform to enhance pipeline value. The reverse split reduced outstanding shares from 81.2 million to 2.7 million under the ticker symbol "ABP." Abpro aims to efficiently create long-term shareholder value through its leaner structure,...
2025-11-03 12:00
Abpro Announces 1-For-30 Reverse Stock Split, Effective October 31, 2025
On October 16, 2025, Abpro Holdings, Inc. (the "Company") filed with the Delaware Secretary of State a Certificate of Amendment to the Certificate of Incorporation of the Company (the "Certificate of Amendment"), which
2025-10-23 05:15
Maxim Group Downgrades Abpro Hldgs to Hold
Maxim Group analyst Jason McCarthy downgrades Abpro Hldgs (NASDAQ:ABP) from Buy to Hold.
2025-10-21 23:01
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers iBio (NASDAQ:IBIO) stock increased by 28.8% to $1.15 during Monday's a...
2025-10-21 05:08
Abpro Holdings Faces Nasdaq Delisting Hearing
Abpro Holdings ( ($ABP) ) has issued an update. Abpro Holdings, Inc. is facing ...
2025-10-18 04:49
